TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy

Bardia, A., Pusztai, L., Albain, K., Ciruelos, E. M., Im, S.-A., Hershman, D., Kalinsky, K., Isaacs, C., Loirat, D., Testa, L., Tokunaga, E., Wu, J., Dry, H., Barlow, W., Kozarski, R., Maxwell, M., Harbeck, N., & Sharma, P. (2024). TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241248336
Authors:
Aditya Bardia
Lajos Pusztai
Kathy S. Albain
Eva Ciruelos
Seock‐Ah Im
Dawn L. Hershman
Kevin Kalinsky
Claudine Isaacs
Thomas Bachelot
Laura Testa
Eriko Tokunaga
Jiong Wu
Hannah Dry
William E. Barlow
Robert Kozarski
Micah J. Maxwell
Nadia Harbeck
Helga B. Salvesen
Affiliated Authors:
Dawn L. Hershman
Columbia Affiliation:
Subjects:
Molecular Research on Breast Cancer (OpenAlex Topic)
HER2 Signaling in Breast Cancer Treatment (OpenAlex Topic)
Chemotherapy-Induced Peripheral Neuropathy in Cancer Treatment (OpenAlex Topic)
Author Keywords:
adjuvant therapy
antibody-drug conjugates
immunotherapy
programmed cell death ligand-1
triple-negative breast cancer
trophoblast cell-surface antigen 2
elink
Publication Type:
Article
Unique ID:
10.1177/17588359241248336
PMID:
38686016
DOI:
10.1177/17588359241248336
Journal:
Therapeutic Advances in Medical Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View Web of Science Record

Record Created: